These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 2890805

  • 1. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever.
    Klugman KP, Gilbertson IT, Koornhof HJ, Robbins JB, Schneerson R, Schulz D, Cadoz M, Armand J.
    Lancet; 1987 Nov 21; 2(8569):1165-9. PubMed ID: 2890805
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
    Mitra M, Shah N, Ghosh A, Chatterjee S, Kaur I, Bhattacharya N, Basu S.
    Hum Vaccin Immunother; 2016 Apr 02; 12(4):939-45. PubMed ID: 26901576
    [Abstract] [Full Text] [Related]

  • 3. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.
    Tacket CO, Pasetti MF, Sztein MB, Livio S, Levine MM.
    J Infect Dis; 2004 Aug 01; 190(3):565-70. PubMed ID: 15243933
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea.
    Kim YR, Yoo JH, Hur JK, Kang JH, Shin WS, Kang MW.
    J Korean Med Sci; 1995 Oct 01; 10(5):314-7. PubMed ID: 8750055
    [Abstract] [Full Text] [Related]

  • 5. Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever.
    Tacket CO, Levine MM, Robbins JB.
    Vaccine; 1988 Aug 01; 6(4):307-8. PubMed ID: 3188615
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
    Bhutta ZA, Capeding MR, Bavdekar A, Marchetti E, Ariff S, Soofi SB, Anemona A, Habib MA, Alberto E, Juvekar S, Khan RM, Marhaba R, Ali N, Malubay N, Kawade A, Saul A, Martin LB, Podda A.
    Lancet Infect Dis; 2014 Feb 01; 14(2):119-29. PubMed ID: 24290843
    [Abstract] [Full Text] [Related]

  • 7. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report.
    Acharya IL, Lowe CU, Thapa R, Gurubacharya VL, Shrestha MB, Cadoz M, Schulz D, Armand J, Bryla DA, Trollfors B.
    N Engl J Med; 1987 Oct 29; 317(18):1101-4. PubMed ID: 3657877
    [Abstract] [Full Text] [Related]

  • 8. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China.
    Yang HH, Wu CG, Xie GZ, Gu QW, Wang BR, Wang LY, Wang HF, Ding ZS, Yang Y, Tan WS, Wang WY, Wang XC, Qin M, Wang JH, Tang HA, Jiang XM, Li YH, Wang ML, Zhang SL, Li GL.
    Bull World Health Organ; 2001 Oct 29; 79(7):625-31. PubMed ID: 11477965
    [Abstract] [Full Text] [Related]

  • 9. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
    Pakkanen SH, Kantele JM, Savolainen LE, Rombo L, Kantele A.
    Vaccine; 2015 Jan 09; 33(3):451-8. PubMed ID: 25433216
    [Abstract] [Full Text] [Related]

  • 10. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
    Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, Kossaczka Z, Bryla DA, Shiloach J, Robbins JB, Schneerson R, Szu SC.
    N Engl J Med; 2001 Apr 26; 344(17):1263-9. PubMed ID: 11320385
    [Abstract] [Full Text] [Related]

  • 11. Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings.
    Zhou WZ, Koo HW, Wang XY, Zhang J, Park JK, Zhu F, Deen J, Acosta CJ, Chen Y, Wang H, Galindo CM, Ochiai L, Park T, von Seidlein L, Xu ZY, Clemens JD.
    Pediatr Infect Dis J; 2007 Nov 26; 26(11):1001-5. PubMed ID: 17984806
    [Abstract] [Full Text] [Related]

  • 12. Persistence of antibodies to the Salmonella typhi Vi capsular polysaccharide vaccine in South African school children ten years after immunization.
    Keddy KH, Klugman KP, Hansford CF, Blondeau C, Bouveret le Cam NN.
    Vaccine; 1999 Jan 26; 17(2):110-3. PubMed ID: 9987143
    [Abstract] [Full Text] [Related]

  • 13. Immunogenicity of a new Salmonella Typhi Vi polysaccharide vaccine--vax-TyVi--in Cuban school children and teenagers.
    Azze RF, Rodríguez JC, Iniesta MG, Marchena XR, Alfonso VM, Padrón FT.
    Vaccine; 2003 Jun 20; 21(21-22):2758-60. PubMed ID: 12798615
    [Abstract] [Full Text] [Related]

  • 14. Immunological evaluation of Vi capsular polysaccharide of Salmonella enterica subsp. Typhi vaccine by serum bactericidal assay.
    Ahmadi H, Tabaraie B, Maleknia S, Shapouri R, Nejati M, Pour Mirza Gholi F, Hedayati M, Sadati M, Zahednia S, Sharifat Salmani A.
    J Med Microbiol; 2013 Feb 20; 62(Pt 2):283-286. PubMed ID: 23105026
    [Abstract] [Full Text] [Related]

  • 15. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India.
    Sur D, Ochiai RL, Bhattacharya SK, Ganguly NK, Ali M, Manna B, Dutta S, Donner A, Kanungo S, Park JK, Puri MK, Kim DR, Dutta D, Bhaduri B, Acosta CJ, Clemens JD.
    N Engl J Med; 2009 Jul 23; 361(4):335-44. PubMed ID: 19625715
    [Abstract] [Full Text] [Related]

  • 16. Development of a synthetic Vi polysaccharide vaccine for typhoid fever.
    Ni Y, Springer MJ, Guo J, Finger-Baker I, Wilson JP, Cobb RR, Turner D, Tizard I.
    Vaccine; 2017 Dec 18; 35(51):7121-7126. PubMed ID: 29150208
    [Abstract] [Full Text] [Related]

  • 17. Vaccines for preventing typhoid fever.
    Anwar E, Goldberg E, Fraser A, Acosta CJ, Paul M, Leibovici L.
    Cochrane Database Syst Rev; 2014 Jan 02; (1):CD001261. PubMed ID: 24385413
    [Abstract] [Full Text] [Related]

  • 18. Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a.
    Darton TC, Jones C, Blohmke CJ, Waddington CS, Zhou L, Peters A, Haworth K, Sie R, Green CA, Jeppesen CA, Moore M, Thompson BA, John T, Kingsley RA, Yu LM, Voysey M, Hindle Z, Lockhart S, Sztein MB, Dougan G, Angus B, Levine MM, Pollard AJ.
    PLoS Negl Trop Dis; 2016 Aug 02; 10(8):e0004926. PubMed ID: 27533046
    [Abstract] [Full Text] [Related]

  • 19. Typhim Vi vaccine against typhoid fever: a clinical trial in Kenya.
    Mirza NB, Wamola IA, Estambale BA, Mbithi E, Poillet M.
    East Afr Med J; 1995 Mar 02; 72(3):162-4. PubMed ID: 7796767
    [Abstract] [Full Text] [Related]

  • 20. Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young children.
    Szu SC, Klugman KP, Hunt S.
    Vaccine; 2014 Apr 25; 32(20):2359-63. PubMed ID: 24630869
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.